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List of abbreviations:  BMDC: bone marrow derived dendritic cell; cDC: conventional 
dendritic cell; pDC: plasmacytoid dendritic cell; Clec1b: C-type lectin domain family 1, 
member B; CLEC-2: C-type lectin-like receptor 2; DC: dendritic cell; FCS: foetal calf 
serum; FL: foetal liver; FRC: fibroblastic reticular cell; GeoMFI: geometric mean 
fluorescence intensity; MLN: mesenteric lymph node; PDPN: podoplanin; RANKL: 
receptor activator of NFB ligand; SLO: secondary lymphoid organ. 
 
 
Abstract 
 
Expression of mouse CLEC-2 has been reported on circulating CD11b
high
 Gr1
high
 myeloid 
cells and dendritic cells (DCs) under basal conditions, as well as on a variety of leucocyte 
subsets following inflammatory stimuli or in vitro cell culture. However, previous studies 
assessing CLEC-2 expression failed to use CLEC-2-deficient mice as negative controls and 
instead relying heavily on single antibody clones. Here, we generated CLEC-2-deficient adult 
mice using two independent approaches and employed two anti-mouse CLEC-2 antibody 
clones to investigate surface expression on haematopoietic cells from peripheral blood and 
secondary lymphoid organs (SLOs). We rule out constitutive CLEC-2 expression on resting 
DCs and show that CLEC-2 is up-regulated in response to LPS-induced systemic 
inflammation in a small subset of activated DCs isolated from the mesenteric lymph nodes 
but not the spleen. Moreover, we demonstrate for the first time that peripheral blood B 
lymphocytes present exogenously derived CLEC-2 and suggest that both circulating B 
lymphocytes and CD11b
high
 Gr1
high
 myeloid cells lose CLEC-2 following entry into SLOs. 
These results have significant implications for our understanding of CLEC-2 physiological 
functions
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Introduction 
 
Many physiological functions are critically regulated by fine-tuned interactions 
between diverse subsets of haematopoietic and non-haematopoietic cells within primary and 
secondary lymphoid organs as well as in the circulation. These interactions are mediated by 
surface receptors or secreted molecules that display complex cellular, spatial and temporal 
expression patterns. A deep understanding of these patterns is required for a full knowledge 
of their physiological significance and for effective therapeutic intervention. For example, 
expression of RANKL by bone osteoblasts regulates bone density while its expression by 
developing thymocytes regulates medullary thymic epithelial cell maturation (for review see 
[1]). 
A similar scenario can be considered for the C-type lectin-like receptor CLEC-2 and 
its ligand podoplanin (PDPN), which are involved in a variety of physiological and 
pathophysiological processes (for review: [2]). While CLEC-2 expression is restricted to 
haematopoietic cells, PDPN is more ubiquitously expressed, with constitutive expression in 
the lungs [3], kidneys [4], brain [3], thymus [5], secondary lymphoid organs (SLOs) [6, 7], 
lymphatic vessels and bones [8]. PDPN expression is also up-regulated at the leading edge of 
tumours and in additional haematopoietic and non-haematopoietic cell-types during 
inflammation (for review: [2]). CLEC-2/PDPN interactions play essential roles in the 
immune system, as they prevent blood-lymph mixing [9-11], are required for lymph-node 
(LN) development [12] and maintenance of LN vascular integrity [12, 13] and contribute to 
the generation of optimal adaptive immune responses [12, 14, 15].  
CLEC-2 surface expression on platelets was first demonstrated in humans [16] and 
soon after in mouse [17] and chicken [18]. The expression of CLEC-2 and its RNA transcript 
– encoded by the Clec1b gene – has also been studied in leucocytes isolated from different 
species leading to a rather confusing mosaic of results. While CLEC-2 is absent from chicken 
leucocytes [18] and restricted to liver-resident Küppfer cells in human [19-22], a much 
broader expression profile of CLEC-2/Clec1b has been reported in rodent leucocytes, 
particularly in mice.  
While one report claims that mouse CLEC-2 surface expression by leucocytes is 
restricted to monocytes and liver-resident Küppfer cells [20], other studies using a different 
antibody clone (17D9), or the fusion protein PDPN-Fc, reported that CLEC-2 is 
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constitutively expressed by CD11b
high
 Gr1
high
 cells isolated from bone marrow and whole 
blood, splenic B lymphocytes, a small subset of splenic natural killer (NK) cells, splenic 
plasmacytoid dendritic cells (pDCs), splenic conventional DCs (cDCs), GM-CSF stimulated 
bone marrow derived DCs (BMDCs), Flt3L BMDC, as well as peripheral lymph node (LN) 
DCs [19, 23, 24]. With the exception of NKT cells and T lymphocytes, in vivo LPS challenge 
has been reported to up-regulate CLEC-2 expression in almost all splenic leucocyte subsets 
as well as peripheral LN DCs [23, 24]. In a thioglycolate-induced peritoneal inflammation 
model, CLEC-2 expression was observed in F4/80
+
 macrophages but not in CD11b
high
 Gr1
high
 
cells [19, 23]. Notably, CLEC-2-deficient negative control cells were not included in most of 
these studies [19, 23]. 
Our study aimed to clarify these contradictory findings and improve our 
understanding of CLEC-2 expression on mouse leucocytes. These results have important 
physiological consequences that will be discussed below.  
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Results and Discussion 
 
 
Peripheral blood B lymphocytes and CD11b
high
 Gr-1
high
 cells present CLEC-2 on their 
surface 
 
Previous studies that investigated the temporal, spatial and pro-inflammatory 
expression of CLEC-2 in the murine adult haematopoietic system have been hampered by the 
high neonatal mortality rate (>95%) of Clec1b
-/-
 mice [10, 20], impeding the inclusion of 
appropriate Clec1b
-/-
 negative control cells in previous studies aiming to define the temporal, 
spatial and post inflammatory expression of CLEC-2 in vivo [19, 23, 24].  
 
To circumvent the neonatal mortality rate of Clec1b
-/-
 mice we developed a 
tamoxifen-inducible Clec1b deleting mouse line (Clec1b
fl/fl
xRosa26
+/creERT2
). After 6 months 
on tamoxifen diet, peripheral blood leucocytes isolated from Clec1b
fl/fl
xRosa26
+/creERT2
 mice 
but not Clec1b
fl/fl
 littermate controls show genomic deletion of the Clec1b locus (Supporting 
Information Fig 1). 
 
In parallel, we investigated CLEC-2 expression on haematopoietic cells isolated from 
lethally irradiated wild-type adult mice reconstituted with foetal liver (FL) cells from E14.5 
Clec1b
+/+
 or Clec1b
-/-
 embryos [25]. This second experimental strategy was used to rule out 
potential side effects of tamoxifen on CLEC-2 expression. It is known that sex steroid 
hormones and their synthetic derivatives (such as tamoxifen) affect haematopoiesis due to the 
presence of oestrogen receptors on most immune cells [26, 27]. Moreover, tamoxifen has 
anti-inflammatory effects that could counteract LPS-mediated pro-inflammatory challenges 
[28-30]. In addition we used two different antibody clones, 17D9 [19, 23] and INU1 [31], 
reported to bind to mouse CLEC-2. 
 
Initially, CLEC-2 expression was measured on circulating platelets, T lymphocytes, B 
lymphocytes and CD11b
high
 Gr-1
high
 cells from Clec1b
fl/fl
xRosa26
+/creERT2
 mice and Clec1b
fl/fl
 
littermates by flow cytometry using the two antibody clones 17D9 and INU1  (Figure 1A and 
Supporting Information Figure 2). Following tamoxifen treatment, Clec1b
fl/fl
xRosa26
+/creERT2
 
platelets showed full abrogation of CLEC-2 expression compared to Clec1b
fl/fl
 littermates 
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using both 17D9 and INU1 (Figure 1A), confirming the efficiency of our inducible genetic 
mouse model. 
On platelets, INU1 staining was found to be weaker than 17D9 staining in both 
control animals (Clec1b
fl/fl
 mice treated with tamoxifen and Clec1b
fl/fl
xRosa26
+/creERT2
 mice 
fed normal diet). Furthermore, the geometric mean fluorescence intensity (GeoMFI) 
associated with 17D9 binding to leucocytes was on average 3-fold lower than that observed 
on platelets (Figure 1A), while INU1 discrimination power on leucocytes was too weak for 
detecting CLEC-2 on them (Figure 1A). As a result, we solely used the 17D9 clone to further 
investigate CLEC-2 expression on leucocytes.  
 
In both the tamoxifen-inducible and radiation chimeric CLEC-2-deficient mouse 
models, the levels of 17D9 binding to circulating B lymphocytes were significantly reduced 
compared to controls (Figure 1A-B), suggesting that peripheral blood B lymphocytes 
constitutively express CLEC-2. Although CLEC-2 appeared to be down-regulated on 
circulating B lymphocytes following LPS treatment in chimeric mice, this was not 
statistically significant (Figure 1B), indicating that activated Clec1b
+/+
 B lymphocytes remain 
positive for CLEC-2 when compared to their activated Clec1b
-/-
 B cell counterparts. 
 
In the absence of LPS-induced inflammation, CD11b
high
 Gr-1
high
 cells (which includes 
a mix of monocytes, granulocytes/neutrophils and a small subset of NK cells [32, 33]) 
isolated from Clec1b
-/-
 reconstituted animals were negative for CLEC-2 compared to 
Clec1b
+/+
 littermates (Figure 1B). This demonstrates that circulating CD11b
high
 Gr-1
high
 cells 
constitutively express CLEC-2 in line with previous reports [19, 23]. However, treatment 
with tamoxifen led to the loss of specific CLEC-2 staining since no significant difference was 
observed between Clec1b
fl/fl
xRosa26
+/creERT2 
mice and their controls (Figure 1A). Tamoxifen 
is known to inhibit B lymphocyte and DC maturation by altering the surface membrane 
expression of molecules such as CD22 on B lymphocytes or MHC-II and CD86 on BMDC 
[34, 35]. Additional uncharacterized phenotypic changes leading to the appearance of new 
CLEC-2-independent binding sites might explain the non-specific binding of 17D9 to 
Clec1b
fl/fl
xRosa26
+/creERT2 
B lymphocytes and CD11b
high
 Gr-1
high
 cells as the wild-type Clec1b 
DNA was undetectable in these cells (Figure 1A, Supporting Information Figure 1).  
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Similarly, after LPS challenge, 17D9 acquired the ability to bind to Clec1b
-/-
 
CD11b
high
 Gr-1
high
 cells leading to a 3.7 fold higher GeoMFI than in equivalent unstimulated 
cells (Figure 1B).  This suggests that 17D9 binds to CD11b
high
 Gr-1
high
 cells in a CLEC-2-
independent manner following LPS-activation. In T lymphocytes there was no evidence for 
17D9 binding in any of our experimental conditions (Supporting Information Figure 3).   
 
From these findings we suggest that mouse peripheral blood B lymphocytes and 
CD11b
high
 Gr-1
high
 cells present CLEC-2 on their surface at a much lower level than platelets. 
These data contrast with the lack of evidence for CLEC-2 expression in peripheral blood 
leucocytes in chickens or humans [18, 21] and with the absence of significant Clec1b 
transcripts in human leucocyte subsets according to microarray analyses on the BioGPS 
database [21, 36]. This indicates that, while CLEC-2 expression by platelets is conserved 
through species, the presence of CLEC-2 in B lymphocytes and CD11b
high
 Gr-1
high
 cells is 
specific to mice. Whether the presence of CLEC-2 on these cells provides any particular 
features to the mouse immunological system remains unknown. Our data add to previous 
reports establishing important differences between the mouse and human immune systems 
[37]. 
 
 
Most SLO-resident leucocytes do not express CLEC-2/Clec1b at steady-state 
 
At steady-state, we observed comparable 17D9 binding to spleen and mesenteric 
lymph node (MLN) B lymphocytes, CD11b
high
 Gr-1
high
 cells, plasmacytoid DCs (pDCs), 
CD11b
neg/int
 conventional DCs (CD11b
neg/int
 cDCs) and CD11b
high
 conventional DCs 
(CD11b
high
 cDCs) isolated from Clec1b
-/-
 radiation chimeras or their wild-type counterparts 
(Figure 2, Supporting Information Figure 4 and Supporting Information Figure 5). These 
results, that demonstrate a lack of CLEC-2 expression on these leucocytes, contradict 
previous observations made using the 17D9 antibody clone and PDPN-Fc recombinant 
protein that suggested that mouse CLEC-2 was constitutively expressed on all these cell types 
in spleen and on peripheral LNs’ cDCs [23, 24]. Moreover, we could not detect significant 
Clec1b transcript levels in most of the leucocyte populations isolated from the spleen and the 
MLN (Figure 2E). The absence of Clec1b transcripts in most resting leucocytes is supported 
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by two independent micro-array analyses performed by the ImmGen [38] and BioGPS [36] 
consortia (Supporting Information Figure 6).  
 
Interestingly, in agreement with the ImmGen database, we did observe that CD11b
int
 
F4/80
pos
 red pulp splenic macrophages express high levels of Clec1b transcripts (Figure 2E). 
However, we were unable to detect surface CLEC-2 on the surface of these cells when 
comparing our foetal liver reconstituted animals (data not shown). Given that F4/80
pos
 red 
pulp splenic macrophages, which express PDPN, play a key physiological role in the 
clearance of senescent blood erythrocytes and platelets by phagocytosis [6, 39, 40], the 
Clec1b transcripts detected in these cells are likely to derive from engulfed platelets. 
 
These results suggest that CLEC-2 surface expression by peripheral blood B 
lymphocytes and CD11b
high
 Gr-1
high
 cells (Figure 1) is lost upon entry into SLOs (Figure 2). 
The majority of mouse B lymphocytes and pre-cDC monocytes migrating from peripheral 
blood toward lymph nodes enter via high endothelial venules (HEV), arriving in the T-cell 
zone which is rich in PDPN
pos
 fibroblastic reticular cells (FRC) [41]. Down-regulation or 
shedding of CLEC-2 by B-lymphocytes and CD11b
high
 Gr-1
high
 cells during their entry 
through the HEV might represent a functional mechanism to prevent inappropriate activation 
of PDPN
pos
 FRCs in the absence of infection. In this context, recent studies demonstrated that 
close interactions between antigen-activated CLEC-2
pos
 DCs and LN PDPN
pos
 FRCs are 
required for mounting an effective immune response by favouring DC recruitment, FRC 
activation and LN swelling [14, 15, 24].  
 
 
Most SLO-resident leucocytes remain CLEC-2-negative following LPS stimulation 
 
CLEC-2 was not up-regulated on splenic and MLN resident B lymphocytes, 
CD11b
high
 Gr-1
high
 cells, pDCs or CD11b
neg/int
 cDCs in response to intraperitoneal LPS 
challenge of Clec1b
-/-
 and Clec1b
+/+
 reconstituted animals (Figure 2A, B, C and Supporting 
Information Figure 5). It has been shown that B lymphocyte stimulation via LPS/TLR4 
favours their emigration from the blood into SLOs [42]. Interestingly, we could not observe 
any CLEC-2
pos
 B lymphocytes in the SLOs of LPS-stimulated mice (Figure 2), supporting the 
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observation that circulating activated B lymphocytes down-regulate CLEC-2 before entering 
into SLOs (Figure 1B). Kerrigan and collaborators have suggested the same CLEC-2 down-
regulation process by circulating CD11b
high
 Gr-1
high
 cells upon reaching inflammatory sites 
[19]. As entry to both SLOs and inflammatory sites requires leucocyte rolling, arrest and 
transendothelial migration [41], it is tempting to suggest that CLEC-2 down-regulation or 
shedding by these leucocytes facilitates the completion of this three-step mechanism. Indeed, 
it has been shown that the shedding of transmembrane molecules is essential for these 
leucocytes transendothelial migrations [43-46]. We hypothesize that CLEC-2 could be lost 
via the same mechanisms.  
 
CD11b
high
 Gr-1
high
 cells, pDCs and CD11b
neg/int
 cDCs isolated from LPS-stimulated 
Clec1b
-/-
 mice exhibited a higher level of 17D9 binding than Clec1b
-/-
 non-challenged 
counterparts. Once again, these results indicate that the 17D9 antibody clone has the capacity 
to bind LPS-stimulated leucocytes in a CLEC-2-independent manner. The lack of Clec1b 
transcript up-regulation in LPS-stimulated leucocytes (Figure 2E) provides further evidence 
to support this conclusion and challenges previously described LPS-induced CLEC-2 up-
regulation by most splenic resident leucocytes and peripheral LN cDCs [23, 24]. 
 
 
MLN but not splenic CD11b
high
 cDCs acquire CLEC-2 following LPS stimulation 
 
In agreement with the results detailed above, CLEC-2 expression was not detected on 
splenic CD11b
high
 cDCs. However a modest but significant increase in staining of MLN-
derived Clec1b
+/+
 CD11b
high
 cDCs compared to Clec1b
-/-
 controls was observed after LPS 
injection (Figure 2D), indicating that LPS-stimulated MLN CD11b
high
 cDCs have the 
capacity to up-regulate CLEC-2 (Figure 2D). However, we could not correlate the appearance 
of CLEC-2 on the membrane with a higher relative amount of Clec1b transcripts in the 
stimulated CD11b
high
 cDCs (Figure 2E), suggesting that LPS stimulation regulates CLEC-2 
expression in MLN CD11b
high
 cDCs via post-transcriptional mechanisms. 
 
Taken together, our results confirmed high levels of CLEC-2 expression on splenic 
platelets (data not shown), while no significant expression of CLEC-2 was observed on most 
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leucocyte populations investigated, both at steady-state and after LPS injection. However, we 
did observe an increase in CLEC-2 expression on activated CD11b
high
 cDCs isolated from the 
MLN. This increase was absent on splenic-activated cDCs. 
The existence of cell-specific and tissue-specific regulation of CLEC-2 expression has 
previously been observed in the context of human rheumatoid arthritis, a chronic 
inflammatory disease where CLEC-2 expression was found to be restricted to tissue 
infiltrating platelets, while absent from activated DCs [22]. In contrast, FITC skin painting, 
FITC footpad immunization, or OVA/CFA subcutaneous injections in mice were found to 
contribute to the generation of an immune response that relies on CLEC-2 expression by 
activated DCs and their interaction with PDPN
pos
 lymphatic endothelial cells and PDPN
pos
 
FRCs [14, 15, 24]. These studies demonstrate that CLEC-2 up-regulation is a characteristic of 
locally activated DCs migrating toward the draining lymph node [14, 15, 24] and not the 
systemic feature of an activated immune system [23]. In accordance with this, we only 
observed CLEC-2 up-regulation by activated DCs in the MLN, a SLO close to the LPS site of 
administration (i.e. the peritoneal cavity), but not in a remote SLO like the spleen. This 
suggests that the MLN CLEC-2
pos
 CD11b
high
 cDCs we observed may have recently migrated 
from the surrounding mesenteric tissue following LPS administration. 
 
 
Normal lymphocyte homeostasis in B-cell Clec1b
-/-
 mice as B-cells do not produce 
CLEC-2  
 
To gain insight into the potential physiological roles of CLEC-2 in B lymphocytes, we 
first visualised the lymph nodes from B lymphocyte-deficient Jh
-/-
 -/- mice and saw no 
evidence of erythrocyte infiltration in the lymph nodes, similar to wild-type animals (Figure 
3A), indicating that CLEC-2 on B lymphocytes does not play an important role in blood-
lymph separation or the maintenance of HEVs. 
 
In order to investigate if CLEC-2 on peripheral blood B lymphocytes contributes to 
lymphocyte homeostasis, we generated mice with a Clec1b
-/-
 deficiency restricted to the B 
cell lineage by mixing Clec1b
-/-
 foetal liver and Jh
-/-
 -/- bone marrow cell suspensions (at a 
1:9 ratio) that we injected in lethally irradiated C57BL/6 recipients (Supporting Information 
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Figure 7A)[47]. The absolute numbers of lymphocytes in the blood, spleen and MLNs were 
monitored (Figure 3B and C, Supplementary Information Figure 7B and C). Both in the blood 
and the SLOs, the absolute numbers of B and T lymphocytes were normal. In the spleen, the 
numbers of follicular, non-follicular and marginal zone Clec1b
-/-
 B lymphocytes were 
comparable to the controls. Contrary to the MLNs, a small increase in CD4
+
 T lymphocytes 
was observed in the spleen of Clec1b
-/-
 animals. However, no-significant increase in naïve 
(CD62L
hi
 CD44
int
) or activated (CD44
hi
 CD62L
-
) CD4
+
 T lymphocytes was noted in these 
animals. Similarly, the CD4
-
 T lymphocytes showed the same level of activation between 
Clec1b
-/-
 and control animals. These results indicate that the deletion of Clec1b gene in the B 
cell lineage has no effect on lymphocyte homeostasis. 
 
Despite the absence of a functional Clec1b gene, peripheral blood Clec1b
-/-
 B 
lymphocytes were stained by 17D9 at the same level as Clec1b
+/+
 B lymphocytes (Figure 
3D). In B lymphocyte Clec1b-deficient mice, 71% of the platelets were CLEC-2
pos
 on 
average (Figure 3D), while the level of CLEC-2 expression by CD11b
high
 Gr-1
high
 cells was 
comparable to that found in controls (Supplementary Information Figure 7D). We compared 
the amount of Clec1b transcripts by quantitative PCR in B lymphocytes isolated from the 
peripheral blood, the MLNs and the spleen.  In all 3 populations, the amount of Clec1b was 
extremely low and at a comparable level (Figure 3E). This last result corroborates a study on 
rat B lymphocytes showing that Clec1b transcripts are hardly detectable in these cells [48]. 
From these observations we conclude that peripheral blood B lymphocytes do not 
intrinsically express CLEC-2. Instead we propose that the CLEC-2 molecules detected on the 
surface of circulating B lymphocytes are derived from MHC-II antigen presentation, 
trogocytosis or exosomes/microparticles attached to the B cell membrane [49].  
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Concluding remarks 
 
 
Our study confirms that CLEC-2 is constitutively expressed by mouse platelets and 
circulating CD11b
high
 Gr1
high
 myeloid cells and shows for the first time that CLEC-2 is 
present on the surface of peripheral blood B lymphocytes. These B cells do not produce 
CLEC-2 but likely acquire CLEC-2 molecules from other yet uncharacterised cell types.  Our 
data suggest that both circulating B lymphocytes and CD11b
high
 Gr1
high
 myeloid cells lose 
CLEC-2 when entering SLOs. This loss of CLEC-2 might depend on the same mechanisms 
that are selectively shedding CD23 and CD62L from leucocytes during the transendothelial 
migration [43, 45, 46]. As CLEC-2 stimulates PDPN
pos
 FRCs in SLOs in order to mount a 
proper immune response [14, 15, 24], we propose that the loss of CLEC-2 by naïve B 
lymphocytes and CD11b
high
 Gr1
high
 myeloid cells entering in the SLOs might be a 
prerequisite to prevent untimely FRCs activation in absence of antigenic challenge. 
The use of animals reconstituted with Clec1b
-/-
 FL and the measurements of Clec1b 
transcripts allowed us to rule out any constitutive CLEC-2 expression by most of the 
leucocyte subpopulations isolated from SLOs. We also demonstrated that isotype controls are 
not adequate when working with the 17D9 antibody clone. Finally we showed that LPS 
peritoneal injection induces CLEC-2 acquisition to the unique MLN activated DCs leucocyte 
population. Taken together with other studies our findings emphasize the notion that the 
expression of CLEC-2 is not only restricted to specific subsets of resting leucocytes and 
platelets but is determined both by the activation state and the anatomical site where immune 
responses take place. 
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Materials and Methods: 
 
 
Mice and diets 
 
Clec1b
+/-
  [25], Clec1b
fl/fl
 [25], Rosa26
+/ERT2cre
 (Jackson Laboratory, ME) [50], 
Clec1b
fl/fl
 x Rosa26
+/ERT2cre
, Jh
-/-
 -/- [51, 52] and BoyJ mice were maintained in the 
Biomedical Services Unit, University of Birmingham. C57BL/6 mice were purchased from 
Harlan, UK.  Animals were fed with FormulaLab Diet 5008 (LabDiet, St-Louis, MO). When 
required, 6-8 week old Clec1b
fl/fl
 x Rosa26
+/ERT2cre
 and their Clec1b
fl/fl
 x Rosa26
+/+
 control 
littermates were continuously fed with tamoxifen-supplemented diet TAM 400 (Harlan, UK). 
For isolation of embryonic foetal liver, the morning of vaginal plug detection was designated 
day 0.5 of gestation. Animal experiments were performed in accordance with UK Home 
Office legislation. 
 
Mouse haematopoietic system reconstitution 
 
C57BL/6 or BoyJ mice (8-10 weeks old) were given Baytril in the drinking water for 
7 days prior to irradiations with two doses of 450rad, 3 hours apart. One hour after the last 
irradiation Clec1b
+/+
 or Clec1b
-/-
 E14.5 foetal liver cells were injected intravenously. For the 
generation of B-cell Clec1b deficient recipients, 2x10
5
 Clec1b
+/+
 or Clec1b
-/-
 E14.5 foetal 
liver cells were mixed with 18x10
5
 Jh
-/-
 -/- bone marrow cells.  Mice were left for 6-8 weeks 
post-injection before analysis or further challenged by intraperitoneal injection of 25g of 
LPS (Chondrex) diluted in PBS or PBS only. Mice were analysed 16-18 hours post LPS or 
PBS injection. Successful LPS injections were confirmed by ≥5% weight loss over this 
period. 
 
Tissue sampling and preparation 
 
In all cases, cell centrifugation was performed at the average force of 275g for 4 min. 
Blood was sampled from the tail vein of Clec1b
fl/fl
; Rosa26
+/ERT2cre
; or Clec1b
fl/fl
 x 
Rosa26
+/ERT2cre
 mice into 20mM EDTA/PBS 1x solution. After centrifugation the supernatant 
was removed and the pellet resuspended in red blood cell lysis buffer (Sigma-Aldrich) at 
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room temperature for 5 minutes. Samples were centrifuged and resuspended in cold PBS 1x, 
2% foetal calf serum (FCS), 2mM EDTA solution and stained for flow cytometry analysis or 
processed for genomic DNA extraction. 
Whole blood from foetal liver reconstituted animals was drawn into acid citrate 
dextrose solution (9:1 volume) from the inferior vena cava under isofluorane anaesthesia and 
mixed to 20mM EDTA/PBS 1x solution. An aliquot of blood was centrifuged and processed 
as described above. 
The spleen and the MLN were harvested into cold 2% FCS RPMI solution (Sigma-
Aldrich). For cell sorting of T-cells, B-cells and NK cells, part of the spleen was 
mechanically dissociated on a 100mm mesh (Greiner Bio-one).  In all the other cases, spleen 
or MLN were teased apart with dissection forceps in a 2% FCS RPMI solution containing 2.5 
mg/mL of Collagenase D (Roche) and 2 mg/mL of DnaseI (Sigma-Aldrich). Cell suspensions 
were kept under magnetic stirring at 37°C for 45 min before centrifugation. Pellets were 
resuspended in a 2% FCS RPMI solution containing 2.5mg/mL of Collagenase/Dispase 
(Roche) and 2mg/mL of DnaseI  (Sigma-Aldrich) and kept under magnetic stirring at 37°C 
for 30 min. Cell suspensions were adjusted to a final EDTA concentration of 5mM by the 
addition of a 0.5M EDTA solution and kept under magnetic stirring at 37°C for 5 min. Cell 
suspensions were centrifuged and the pellets resuspended in red blood cell lysis buffer 
(Sigma-Aldrich) as described above before processing for FACS staining. 
 
Antibodies, FACS analysis and cell sorting 
 
The full list of antibodies used is provided in Supporting Information Table 1. Anti-mouse 
CLEC-2-FITC 17D9 clone was mainly obtained from a commercial provider (AbD Serotec, 
17D9) and compared to rat IgG2b-FITC (AbD Serotec, MCA1125FT). For some 
experiments, purified 17D9 (a kind gift from Caetano Reis e Sousa, Cancer Research UK, 
London) and purified rat IgG2b (R&D Systems) were used. Purified anti-mouse CLEC-2 
INU1 clone (a kind gift from Bernhard Nieswandt, University of Würzburg, Germany) was 
used in conjunction with purified rat IgG1k (Biolegend, 400402). All purified antibodies 
were conjugated to AlexaFluor®488 using a monoclonal antibody labeling kit (Invitrogen). 
Cells were stained with antibodies at 4°C in the dark in PBS 1x, 2 % FCS, 2 mM 
EDTA solution. Cells were washed and centrifuged twice before being resuspended in a cold 
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a PBS 1x, 2 % FCS, 2 mM EDTA, 1mg/mL DAPI solution. Flow cytometry acquisitions 
were performed on a 3 laser (405 nm, 488 nm, 633 nm) Cyan (Beckman Coulter) using 
Summit v4.3 software (Beckman Coulter). Flow cytometry cell sorting were performed on a 
MoFlo high-speed cell sorter and Astrios cell sorter (Beckman Coulter) using Summit 
software (Beckman Coulter).  FACS data were analysed with FlowJo software 8.7 (Tristar). 
 
Quantitative PCR 
 
Total bone marrow was flushed with 2% FCS RPMI from the tibia and femur of both hind 
legs. A tenth of the cell suspension was centrifuged, the supernatant was removed and pellets 
were snap frozen on dry ice. Flow cytometry cell sorted cells were collected in PBS 1x, 2% 
FCS, 2mM EDTA solution, centrifuged, pelleted, snap frozen on dry ice and stored at -80°C. 
mRNA was extracted using a ‘RNeasy Microkit’ (Qiagen) following the manufacturers 
instructions. cDNA was generated using the ‘High Capacity Reverse Transcription’ kit and 
random primers mix (Applied Biosystems). RT-PCR reaction settings were: 25°C, 10min; 
37°C, 120min; 85°C, 10min. The cDNA obtained was diluted 1/2 with RNase-free/DNase-
free water (Qiagen), pre-amplified using the ‘TaqMan Pre-Amp Master Mix’ kit (Applied 
Biosystems) and the TaqMan probes (Applied Biosystems) specific for murine b-actin 
(Actnb, probe n°:  Mm_01205647-g1), ß-2microglobulin (B2m, probe n°: Mm_00437762-
m1) and CLEC-2 (Clec1b, probe n°: Mm_0183353-m1). The pre-amplification PCR reaction 
settings were 95°C, 10min followed by 10 cycles: [95°C, 15sec; 65°C, 4min]. These pre-
amplified cDNA were diluted 1/5 with RNase-free/DnaseDNase-free water (Qiagen). The 
TaqMan probes based quantitative PCR were set-up on a 384 well/plate using ‘TaqMan Gene 
Expression Master Mix’ (Applied Biosystems) and the TaqMan probes for the murin Actnb , 
B2m and Clec1b mentioned above. The quantitative PCR reactions were run on a 7900HT 
quantitative PCR machine (Applied Biosystems) at 50°C, 2 min; 95°C, 10 min; 40 cycles: 
[95°C, 15 sec; 60°C, 1 min]. 
 
Statistical Analysis 
 
All statistical analyses were performed on Prism v4.0 (GraphPad Software, CA) using two-
tailed Mann-Whitney tests with 95% confidence interval. 
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Figure 1. CLEC-2 is present at the surfaces of peripheral blood platelets, B cells and 
CD11b
high
 Gr-1
high
 cells at steady-state.  (A) Clec1b
fl/fl
xRosa26
+/creERT2
 (CRE TAM) and 
Clec1b
fl/fl 
littermate controls (LOX TAM) were fed tamoxifen-supplemented diet from 6-8 
weeks old for 6 months. Clec1b
fl/fl
xRosa26
+/creERT2
 mice (11-14 weeks old) fed conventional 
diet only were used as controls (CRE Control). Blood was drawn from the tail vein, the 
erythrocytes were lysed and the remaining leucocytes stained with fluorochrome-conjugated 
antibodies. CLEC-2 expression expression on platelets, B lymphocytes and myeloid cells was 
assessed using the 17D9 (white symbols) or INU1 (black symbols) antibody clones compared 
to their respective isotype controls by flow cytometry. The staining intensities are expressed 
by the geometric mean of fluorescence intensity (Geo.M.F.I). (B) Wild-type animals were 
lethally irradiated (2 x 450 rad) and injected intravenously with fetal liver cells (FL) from 
Clec1b
+/+
 (WT FL) or Clec1b
-/-
 (KO FL) E14.5 embryos. Six to eight weeks post-injection 
animals were challenged with 25g LPS by intraperitoneal injection (WT FL LPS or KO FL 
LPS, black symbols) and compared to non-challenged animals (WT FL Control or KO FL 
Control, white symbols). 16-18 hours post LPS injection, blood was harvested by full 
exsanguination and processed as described above.  Each symbol represents a sample from an 
individual mouse. Bars represent the means.  The graphs summarize 1-3 independent 
experiments pooled together. Statistical significance was measured by a Mann-Whitney test 
with a 95% confidence interval, where: *: P<0.05; **: P<0.005; ***: P<0.0005; N.S.: not 
significant. 
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Figure 2. In secondary lymphoid organs, CLEC-2 expression by leucocytes is restricted 
to a subpopulation of activated DC.  At 6-8 weeks old, Clec1b
+/+
 (WT FL) or Clec1b
-/-
 (KO 
FL) foetal liver chimeras were challenged with 25g LPS by intraperitoneal injection (WT FL 
LPS or KO FL LPS, black symbols) and compared to non-challenged animals (WT FL 
Control or KO FL Control, white symbols). 16-18 hours after LPS injections, the spleen and 
mesenteric lymph node (MLN) were harvested, the erythrocytes were lysed and the 
remaining leucocytes stained with fluorochrome-conjugated antibodies. CLEC-2 expression 
on (A) B cells, (B) CD11b
high
 Gr-1
high
 cells, (C) CD11b
neg/int 
DCs and (D) CD11b
high
 DCs was 
assessed using the 17D9 antibody compared to its respective isotype control by flow 
cytometry. The staining intensities are expressed as the geometric mean of fluorescence 
intensity (Geo.M.F.I). Each symbol represents a sample from an individual mouse and bars 
represent means. The graphs summarize 3 independent experiments pooled together. (E) 
Relative expression of Clec1b transcript in leucocytes isolated from the spleen and the MLN. 
C57BL/6 mice were injected intraperitoneally with PBS (white bars) or 25g LPS (black 
bars). 16-18 hours later the spleen and MLN were harvested, the erythrocytes were lysed and 
the remaining leucocytes stained.  Leucocyte populations were isolated by FACS based on 
the following phenotypes: T cells (T): DAPI
neg
 CD41
neg
 F4/80
neg
 CD11c
neg
 CD19
neg
 B220
neg
 
CD3pos CD8/CD4pos; B cells (B): DAPIneg CD41neg F4/80neg CD11cneg CD8neg CD3neg 
B220
pos
 CD19
pos
; NK cells (NK): DAPI
neg
 CD41
neg
 CD19
neg
 CD8neg CD4neg CD3neg 
NK1.1/NKp46
pos
; CD11b
pos
 F4/80
pos
 cells: DAPI
neg
 CD41
neg
 CD19
neg
 CD3neg F4/80neg 
CD11b
pos
; F4/80
pos
 CD11b
int
 cells: DAPI
neg
 CD41
neg
 CD19
neg
 CD3neg CD11bint F4/80pos; 
cDC CD11b
neg/int
 cells: DAPI
neg
 CD41
neg
 CD19
neg
 CD3neg B220neg CD11cpos CD11bneg/int; 
cDC CD11b
high
 cells: DAPI
neg
 CD41
neg
 CD19
neg
 CD3neg B220neg CD11cpos CD11bhigh. After 
mRNA isolation and cDNA pre-amplification for the genes of interest, the samples were 
analysed by quantitative PCR. The signal for Clec1b was normalised against the house-
keeping gene Actnb (-actin). Total bone marrow (Total BM) isolated from PBS-injected 
mice was used as positive control while the T cells coming from these animals were used as 
reference to set the arbitrary unit. Each population was isolated from three to five 
independent cell sorting experiments including one LPS-injected and one PBS-injected 
mouse for each cell sorting, with the exception of the F4/80
pos
 CD11b
int
 control and LPS-
stimulated cells for which n=2 experiments. Data are shown as mean + SEM. 
Statistical significance was measured by a Mann-Whitney test with a 95% confidence interval 
where: *: P<0.05; **: P<0.005; ***: P<0.0005; N.S.: not significant. 
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Figure 3. B lymphocyte-specific Clec1b deficiency does not affect lymphocyte 
homeostasis as CLEC-2 molecules on circulating B cells are exogenously derived. (A) 
Cervical lymph nodes (CLNs), inguinal lymph nodes (ILNs) and mesenteric lymph node 
(MLN) were isolated from wild-type (WT) and B-cell deficient Jh
-/-
 -/- mice and imaged. The 
picture is representative of 5 wild-type and 6 B-cell deficient mice. Red bars represent 5 mm. 
(B-D) Irradiated recipient mice were reconstituted with a mix of 2x10
5
 Clec1b
+/+
 or Clec1b
-/-
 
E14.5 foetal liver cells and 18x10
5
 Jh
-/-
 -/- bone marrow cells. 7-9 weeks later, the blood, 
spleen and mesenteric lymph nodes were isolated and analyzed by flow cytometry to 
determine (B, C) leucocyte numbers and (D) CLEC-2 expression was assessed using the 
17D9 antibody compared to its respective isotype control. Each symbol represents an 
individual mouse and bars represent means. The graphs summarize two independent 
experiments pooled together. (E) Platelets and B lymphocytes were isolated from the blood, 
MLN and the spleen of C57BL/6 mice by FACS, based on the following phenotypes: 
Platelets: FSC
low
 CD41
pos
; B cells: FSC
hi
 CD41
neg
 DAPI
neg
 CD3neg CD19pos. After mRNA 
isolation and cDNA synthesis, the relative expression of Clec1b transcripts were analysed by 
quantitative PCR. The signals for Clec1b was normalised against the house-keeping gene 
Actnb (-actin). Total bone marrow (Total BM) was used as positive control and reference to 
set the arbitrary unit. Each population was isolated from three independent cell sorting 
experiments, including 1-2 mice for each cell sorting, and one quantitative PCR was ran from 
each cell sorting. The graphs summarize these 3 independent quantitative PCRs pooled 
together and data are shown as mean + SEM. 
Statistical significance was measured by a Mann-Whitney test with a 95% confidence interval 
where: *: P<0.05; **: P<0.005; ***: P<0.0005; N.S.: not significant. 
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